title: Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.
abstract: The evolution of fasting glucose, triglyceride, and total and high-density lipoprotein (HDL) cholesterol level and the factors associated with development of clinically significant abnormalities in these metabolic parameters at 6 months were assessed in 353 consecutive human immunodeficiency virus (HIV)-infected patients who were receiving antiretroviral therapy containing lopinavir-ritonavir. Although glucose and HDL cholesterol levels did not change, triglyceride and total cholesterol levels significantly increased (P<.0001 for each), as did the proportion of patients with a triglyceride level of >400 mg/dL and a total cholesterol level of >240 mg/dL (P=.002). A baseline triglyceride level of >400 mg/dL and a baseline total cholesterol level of >240 mg/dL were identified as independent factors predicting clinically significant hypertriglyceridemia and hypercholesterolemia, respectively, at 6 months. These findings may have clinical implications when the therapeutic option of lopinavir-ritonavir is considered.
authors.affiliation: Hospital Clínic-Institut d'Investigaciones Biomèdiques August Pi i Sunyer, Valencia, Spain. esteban@fundsoriano.es
authors.forename: Esteban
authors.initials: E
authors.lastname: Martínez
authors.forename: Pere
authors.initials: P
authors.lastname: Domingo
authors.forename: María J
authors.initials: MJ
authors.lastname: Galindo
authors.forename: Ana
authors.initials: A
authors.lastname: Milinkovic
authors.forename: Juan A
authors.initials: JA
authors.lastname: Arroyo
authors.forename: Francisco
authors.initials: F
authors.lastname: Baldovi
authors.forename: María
authors.initials: M
authors.lastname: Larrousse
authors.forename: Agathe
authors.initials: A
authors.lastname: León
authors.forename: Elisa
authors.initials: E
authors.lastname: de Lazzari
authors.forename: José M
authors.initials: JM
authors.lastname: Gatell
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D002784:Cholesterol / Q000378:metabolism; D008076:Cholesterol, HDL / Q000378:metabolism; D005260:Female; D006678:HIV; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D061466:Lopinavir; D008297:Male; D008659:Metabolic Diseases / Q000139:chemically induced* / Q000453:epidemiology; D011744:Pyrimidinones / Q000009:adverse effects*; D012307:Risk Factors; D019438:Ritonavir / Q000009:adverse effects*; D014280:Triglycerides / Q000378:metabolism
chemical_list: D008076:Cholesterol, HDL; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D014280:Triglycerides; D061466:Lopinavir; D002784:Cholesterol; D019438:Ritonavir